Mereo BioPharma Group (NASDAQ:MREO) Now Covered by Lifesci Capital

Equities research analysts at Lifesci Capital began coverage on shares of Mereo BioPharma Group (NASDAQ:MREO) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set an “outperform” rating and a $10.00 price target on the stock. Lifesci Capital’s price objective points to a potential upside of 194.99% from the company’s previous close.

Several other analysts have also recently issued reports on MREO. Cantor Fitzgerald raised shares of Mereo BioPharma Group to a “strong-buy” rating in a research note on Sunday, December 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $7.00 price target on shares of Mereo BioPharma Group in a report on Tuesday, November 12th. Finally, Jefferies Financial Group started coverage on Mereo BioPharma Group in a research note on Friday, December 6th. They set a “buy” rating and a $7.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Mereo BioPharma Group currently has a consensus rating of “Buy” and a consensus price target of $7.83.

Mereo BioPharma Group Stock Up 1.2 %

Shares of NASDAQ:MREO opened at $3.39 on Tuesday. The business’s 50 day moving average price is $3.90 and its 200-day moving average price is $4.02. Mereo BioPharma Group has a 1 year low of $3.11 and a 1 year high of $5.02.

Institutional Investors Weigh In On Mereo BioPharma Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers increased its holdings in Mereo BioPharma Group by 70.9% in the 2nd quarter. Rhumbline Advisers now owns 6,958 shares of the company’s stock valued at $25,000 after purchasing an additional 2,887 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Mereo BioPharma Group by 58.1% in the 3rd quarter. GAMMA Investing LLC now owns 10,693 shares of the company’s stock valued at $44,000 after buying an additional 3,928 shares during the period. State Street Corp acquired a new position in Mereo BioPharma Group during the 3rd quarter worth about $195,000. GSA Capital Partners LLP purchased a new position in Mereo BioPharma Group during the 3rd quarter valued at about $276,000. Finally, Fred Alger Management LLC grew its position in Mereo BioPharma Group by 108.1% in the 3rd quarter. Fred Alger Management LLC now owns 102,582 shares of the company’s stock valued at $422,000 after acquiring an additional 53,278 shares in the last quarter. 62.83% of the stock is owned by hedge funds and other institutional investors.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.